Semble, a UK-based clinical platform, has raised £30 million in a Series C funding round led by European growth investor Revaia. The company was co-founded by CEO Christoph Lippuner and built around a simple premise: the problem in healthcare is not a shortage of software, but an excess of software that does not work together. Semble's platform connects scheduling, clinical records, billing, diagnostics, and patient communications in one place, so providers can manage care without switching between systems.
Private healthcare in the UK has been growing steadily. Total admissions reached 953,000 in 2025, the highest figure ever recorded and the fourth consecutive year of records, according to the Private Healthcare Information Network. The market was valued at $13.75 billion in 2024 and is projected to reach $18.56 billion by 2033, according to DataM Intelligence, with growth driven by more people taking out private medical insurance and paying for care directly. That expansion puts real pressure on providers, many of whom are still running operations across a patchwork of disconnected tools.
The round includes new investment from Partech, alongside continued backing from existing investors Mercia Ventures and Octopus Ventures.
The technology problem in private healthcare has built up gradually. Providers have added tools one at a time over the years, often choosing the best available option for each task in isolation. Appointments get managed in one system. Patient records in another. Billing somewhere else. Over time, those separate systems create more work, not less, and clinicians end up spending hours on administration that could be spent on patients.
Semble's approach is to sit across all those systems rather than replace them. The platform integrates with over 1,200 external tools, including diagnostics software, billing platforms, labs, and customer management systems. Healthcare groups can connect their existing tools to Semble without starting from scratch, which makes adoption significantly easier.
"Semble is building the system of action for modern healthcare — a platform with genuine clinical depth, real scale and the trust of healthcare providers across the UK and France. The European healthcare market is being reshaped by technology, by demand and by shifting patient expectations — and Semble is exceptionally well positioned to lead it." — Morgan Kessous, Partner at Revaia
The funding will go toward three priorities: expanding into larger healthcare groups, growing its presence in France, and developing its position as an AI coordination layer for care delivery. Semble entered the French market less than a year ago and has already demonstrated significant regulatory maturity there, which is meaningful given how complex French healthcare regulation can be for foreign platforms.
Headcount has also grown fast. The company increased its workforce by over 50% between December 2024 and the announcement date, a sign that this round is financing real operational growth, not just product development.
On the AI side, Semble's goal is to become the infrastructure through which AI tools reach clinicians, rather than building separate AI products. Healthcare AI is gradually moving beyond simple scheduling and admin tasks toward more substantive functions like clinical decision support and real-time coordination of care. Semble wants to be the layer that makes those capabilities accessible to providers already using its platform.
"For years, the industry has tried to address complex systemic issues through disconnected point solutions, but fragmented technology often adds operational complexity for healthcare providers and creates an interrupted experience for patients. What healthcare organisations need is intelligent orchestration across the entire care journey. The practices and groups that win over the next decade will be the ones that deliver the best patient experience end-to-end." — Christoph Lippuner, CEO and co-founder of Semble
Semble was built to address fragmentation in outpatient care, where patients move between appointments, specialists, labs, and billing, and providers need to track all of it. The platform covers the full range of day-to-day clinical operations: scheduling, electronic health records, telehealth consultations, payments, and patient communications. More than 16,000 healthcare professionals use it daily, across 80 medical specialities.
Its scale in the UK is considerable. Over 10 million patients, roughly one in six people in the country, have received care from a clinician working on Semble. The company's 1,700 customers include Nuffield Health, Welbeck, Midland Health, London Doctors Clinic, Modality, and ProblemShared. TIME named Semble one of the World's Top HealthTech Companies for 2025.
The platform is designed to be open, meaning it connects with other tools rather than locking providers into a closed system. That architecture has helped it serve clients ranging from solo practitioners to large hospital groups.
Revaia, which led the Series C, is a Paris-based growth investor with offices in London, Munich, and Berlin, and a presence in North America. The firm focuses on technology companies at the growth stage, particularly those with sustainability built into their operations.
Partech is a new addition to Semble's investor base. Founded 40 years ago in San Francisco, the firm is now headquartered in Paris with additional offices in Berlin, Dakar, Dubai, Nairobi, and San Francisco. It manages over $3 billion in assets across 220 companies in 40 countries. Its Partech Impact fund backs European B2B technology companies in sectors including healthcare.
Mercia Ventures and Octopus Ventures return as existing investors. Combined, the four firms bring capital from early-stage venture through to growth and impact investing.
